Management of primary sclerosing cholangitis: Conventions and controversies

Canadian Journal of Gastroenterology

Volumn 26, Issue 5, 2012, Pages 261-268

  Chandok, Natasha ^a   Hirschfield, Gideon M ^b,c  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Diagnosis; Liver transplantation; Pathogenesis; Primary sclerosing cholangitis

Indexed keywords

ALKALINE PHOSPHATASE; AZATHIOPRINE; CALCIUM; CELL ADHESION MOLECULE; CHEMOKINE; COLCHICINE; CORTICOSTEROID; CYCLOSPORIN; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 2; METHOTREXATE; METRONIDAZOLE; MINOCYCLINE; MUCOSAL ADDRESSIN CELL ADHESION MOLECULE 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENICILLAMINE; PLACEBO; TACROLIMUS; URSODEOXYCHOLIC ACID; VITAMIN D;

ADAPTIVE IMMUNITY; ALKALINE PHOSPHATASE BLOOD LEVEL; CHOLANGIOGRAPHY; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DISEASE COURSE; ENTERITIS; FATIGUE; GENOME ANALYSIS; HUMAN; IMMUNOMODULATION; INNATE IMMUNITY; LIVER TRANSPLANTATION; LYMPHOCYTIC INFILTRATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PRURITUS; REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 84861171625     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2012/426430     Document Type: Review

References (86)

1. Hirschfield GM, Heathcote EJ, Gershwin ME. Pathogenesis of cholestatic liver disease and therapeutic approaches. Gastroenterology 2010;139:1481-96.
2. Weismuller TJ, Wedemeyer J, Kubicka S, Strassburg CP, Manns MP. The challenges in primary sclerosing cholangitis - aetiopathogenesis, autoimmunity, management and malignancy. J Hepatol 2008;48(Suppl 1):S38-57.
3. 4-associated cholangitis and primary sclerosing cholangitis - overlapping or separate diseases? J Hepatol 2009;51:398-402.
4. Chapman R, Fevery J, Kalloo A, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010;51:660-78.
5. EASL Clinical Practice Guidelines: Management of cholestatic liver diseases. J Hepatol 2009;51:237-67.
6. Lindkvist B, Benito de Valle M, Gullberg B, Bjornsson E. Incidence and prevalence of primary sclerosing cholangitis in a defined adult population in Sweden. Hepatology 2010;52:571-7.
7. Bambha K, Kim WR, Talwalkar J, et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology 2003;125:1364-9. (Pubitemid 37409756)
8. Molodecky NA, Kareemi H, Parab R, et al. Incidence of primary sclerosing cholangitis: A systematic review and meta-analysis. Hepatology 2011;53:1590-9.
9. Bowlus CL. Cutting edge issues in primary sclerosing cholangitis. Clin Rev Allerg Immunol 2011;41:139-50.
10. Borchers AT, Shimoda S, Bowlus C, Keen CL, Gershwin ME. Lymphocyte recruitment and homing to the liver in primary biliary cirrhosis and primary sclerosing cholangitis. Semin Immunopathol 2009;31:309-22.
11. Pollheimer MJ, Trauner M, Fickert P. Will we ever model PSC? - "It's hard to be a PSC model!" Clin Res Hepatol Gastroenterol 2011;35:792-804.
12. Henckaerts L, Jaspers M, Van Steenbergen W, et al. Cystic fibrosis transmembrane conductance regulator gene polymorphisms in patients with primary sclerosing cholangitis. J Hepatol 2009;50:150-7.
13. Pall H, Zielenski J, Jonas MM, et al. Primary sclerosing cholangitis in childhood is associated with abnormalities in cystic fibrosis-mediated chloride channel function. J Pediatr 2007;151:255-9. (Pubitemid 47284133)
14. -/- mice results in bile duct injury. Am J Physiol Gastrointest Liver Physiol 2004;287:G491-6.
15. Hov JR, Keitel V, Schrumpf E, Haussinger D, Karlsen TH. TGR5 Sequence variation in primary sclerosing cholangitis. Digestive Dis 2011;29:78-84.
16. Keitel V, Ullmer C, Haussinger D. The membrane-bound bile acid receptor TGR5 (Gpbar-1) is localized in the primary cilium of cholangiocytes. Biological Chem 2010;391:785-9.
17. Karlsen TH, Franke A, Melum E, et al. Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology 2010;138:1102-11.
18. Melum E, Franke A, Schramm C, et al. Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. Nature Genet 2011;43:17-9.
19. Karlsen TH, Boberg KM, Olsson M, et al. Particular genetic variants of ligands for natural killer cell receptors may contribute to the HLA associated risk of primary sclerosing cholangitis. J Hepatol 2007;46:899-906.
20. Norris S, Kondeatis E, Collins R, et al. Mapping MHC-encoded susceptibility and resistance in primary sclerosing cholangitis: The role of MICA polymorphism. Gastroenterology 2001;120:1475-82. (Pubitemid 32322322)
21. Adams DH. Mucosal lymphocytes in the pathogenesis of the hepatic complications of inflammatory bowel disease. Clin Med 2008;8:28-9.
22. Eksteen B, Mora JR, Haughton EL, et al. Gut homing receptors on CD8 T cells are retinoic acid dependent and not maintained by liver dendritic or stellate cells. Gastroenterology 2009;137:320-9.
23. Oo YH, Shetty S, Adams DH. The role of chemokines in the recruitment of lymphocytes to the liver. Digestive Dis 2010;28:31-44.
24. Hirano K, Tada M, Isayama H, et al. Long-term prognosis of autoimmune pancreatitis with and without corticosteroid treatment. Gut 2007;56:1719-24. (Pubitemid 350206299)
25. Aljiffry M, Renfrew PD, Walsh MJ, Laryea M, Molinari M. Analytical review of diagnosis and treatment strategies for dominant bile duct strictures in patients with primary sclerosing cholangitis. HPB 2011;13:79-90.
26. Moff SL, Kamel IR, Eustace J, et al. Diagnosis of primary sclerosing cholangitis: A blinded comparative study using magnetic resonance cholangiography and endoscopic retrograde cholangiography. Gastrointest Endosc 2006;64:219-23. (Pubitemid 44062484)
27. Eracleous E, Genagritis M, Papanikolaou N, et al. Complementary role of helical CT cholangiography to MR cholangiography in the evaluation of biliary function and kinetics. Eur Radiol 2005;15:2130-9. (Pubitemid 41403511)
28. Levy MJ, Baron TH, Clayton AC, et al. Prospective evaluation of advanced molecular markers and imaging techniques in patients with indeterminate bile duct strictures. Am J Gastroenterol 2008;103:1263-73. (Pubitemid 351677975)
29. Harbin WP, Mueller PR, Ferrucci JT Jr. Transhepatic cholangiography: Complicatons and use patterns of the fine-needle technique: A multi-institutional survey. Radiology 1980;135:15-22. (Pubitemid 10155056)
30. Brand M, Bizos D, O'Farrell P Jr. Antibiotic prophylaxis for patients undergoing elective endoscopic retrograde cholangiopancreatography. Cochrane Database Syst Rev 2010;(10):CD007345.
31. Abu-Hamda EM, Baron TH. Endoscopic management of cholangiocarcinoma. Semin Liv Dis 2004;24:165-75. (Pubitemid 38738345)
32. Desa LA, Akosa AB, Lazzara S, Domizio P, Krausz T, Benjamin IS. Cytodiagnosis in the management of extrahepatic biliary stricture. Gut 1991;32:1188-91.
33. Mansfield JC, Griffin SM, Wadehra V, Matthewson K. A prospective evaluation of cytology from biliary strictures. Gut 1997;40:671-7. (Pubitemid 27278338)
34. Eaton JE, Silveira MG, Pardi DS, et al. High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol 2011;106:1638-45.
35. Siqueira E, Schoen RE, Silverman W, et al. Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. Gastrointest Endosc 2002;56:40-7. (Pubitemid 41115047)
36. Lindberg B, Enochsson L, Tribukait B, Arnelo U, Bergquist A. Diagnostic and prognostic implications of DNA ploidy and S-phase evaluation in the assessment of malignancy in biliary strictures. Endoscopy 2006;38:561-5. (Pubitemid 43978521)
37. Mitchell SA, Bansi DS, Hunt N, Von Bergmann K, Fleming KA, Chapman RW. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 2001;121:900-7.
38. Olsson R, Boberg KM, de Muckadell OS, et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: A 5-year multicenter, randomized, controlled study. Gastroenterology 2005;129:1464-72.
39. Pardi DS, Loftus EV, Jr., Kremers WK, Keach J, Lindor KD. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003;124:889-93. (Pubitemid 36389790)
40. Lindor KD, Kowdley KV, Luketic VA, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009;50:808-14.
41. Tsai S, Pawlik TM. Primary sclerosing cholangitis: The role of extrahepatic biliary resection. Advances Surg 2009;43:175-88.
42. Kremer AE, Oude Elferink RP, Beuers U. Pathophysiology and current management of pruritus in liver disease. Gastroenterol Clin Biol 2011, January (Epub ahead of print).
43. Pares A, Herrera M, Aviles J, Sanz M, Mas A. Treatment of resistant pruritus from cholestasis with albumin dialysis: Combined analysis of patients from three centers. J Hepatol 2010;53:307-12.
44. Angulo P, Grandison GA, Fong DG, et al. Bone disease in patients with primary sclerosing cholangitis. Gastroenterology 2011;140:180-8.
45. Zein CO, Lindor KD, Angulo P. Prevalence and predictors of esophageal varices in patients with primary sclerosing cholangitis. Hepatology 2004;39:204-10. (Pubitemid 38461483)
46. Bressler B, Pinto R, El-Ashry D, Heathcote EJ. Which patients with primary biliary cirrhosis or primary sclerosing cholangitis should undergo endoscopic screening for oesophageal varices detection? Gut 2005;54:407-10. (Pubitemid 40299099)
47. Loftus EV Jr, Harewood GC, Loftus CG, et al. PSC-IBD: A unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 2005;54:91-6. (Pubitemid 40007225)
48. Leddin D, Hunt R, Champion M, et al. Canadian Association of Gastroenterology and the Canadian Digestive Health Foundation: Guidelines on colon cancer screening. Can J Gastroenterol 2004;18:93-9. (Pubitemid 38418034)
49. Loftus EV Jr, Sandborn WJ, Tremaine WJ, et al. Risk of colorectal neoplasia in patients with primary sclerosing cholangitis. Gastroenterology 1996;110:432-40. (Pubitemid 26043876)
50. Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: A systematic review and meta-analysis of observational studies. Am J Gastroenterol 2005;100:1345-53. (Pubitemid 40904360)
51. Boberg KM, Chapman RW, Hirschfield GM, Lohse AW, Manns MP, Schrumpf E. Overlap syndromes: The International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol 2011;54:374-85.
52. Gheorghe L, Iacob S, Gheorghe C, et al. Frequency and predictive factors for overlap syndrome between autoimmune hepatitis and primary cholestatic liver disease. Eur J Gastroenterol Hepatol 2004;16:585-92. (Pubitemid 38703867)
53. Muratori L, Cassani F, Pappas G, et al. The hepatitic/cholestatic "overlap" syndrome: An Italian experience. Autoimmunity 2002;35:565-8. (Pubitemid 36321899)
54. Kaya M, Angulo P, Lindor KD. Overlap of autoimmune hepatitis and primary sclerosing cholangitis: An evaluation of a modified scoring system. J Hepatol 2000;33:537-42.
55. Gregorio GV, Portmann B, Karani J, et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: A 16-year prospective study. Hepatology 2001;33:544-53. (Pubitemid 32185215)
56. Mieli-Vergani G, Vergani D. Unique features of primary sclerosing cholangitis in children. Curr Opin Gastroenterol 2010;26:265-8.
57. Bjornsson E, Olsson R, Bergquist A, et al. The natural history of small-duct primary sclerosing cholangitis. Gastroenterology 2008;134:975-80. (Pubitemid 351451987)
58. Singal AK, Stanca CM, Clark V, et al. Natural history of small duct primary sclerosing cholangitis: A case series with review of the literature. Hepatol Int 2011;5:808-13.
59. Burak K, Angulo P, Pasha TM, Egan K, Petz J, Lindor KD. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol 2004;99:523-6. (Pubitemid 38524134)
60. Boberg KM, Bergquist A, Mitchell S, et al. Cholangiocarcinoma in primary sclerosing cholangitis: Risk factors and clinical presentation. Scand J Gastroenterol 2002;37:1205-11. (Pubitemid 35189610)
61. Heffron TG, Smallwood GA, Ramcharan T, et al. Duct-to-duct biliary anastomosis for patients with sclerosing cholangitis undergoing liver transplantation. Transplant Proc 2003;35:3006-7. (Pubitemid 38102114)
62. Wiesner RH. Liver transplantation for primary sclerosing cholangitis: Timing, outcome, impact of inflammatory bowel disease and recurrence of disease. Best Pract Res Clin Gastroenterol 2001;15:667-80. (Pubitemid 32747018)
63. Florman S, Schiano T, Kim L, et al. The incidence and significance of late acute cellular rejection (>1000 days) after liver transplantation. Clin Transplant 2004;18:152-5. (Pubitemid 38404645)
64. Graziadei IW, Wiesner RH, Marotta PJ, et al. Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis. Hepatology 1999;30:1121-7. (Pubitemid 29510847)
65. Graziadei IW, Wiesner RH, Batts KP, et al. Recurrence of primary sclerosing cholangitis following liver transplantation. Hepatology 1999;29:1050-6. (Pubitemid 29168735)
66. Campsen J, Zimmerman MA, Trotter JF, et al. Clinically recurrent primary sclerosing cholangitis following liver transplantation: A time course. Liver Transplant 2008;14:181-5. (Pubitemid 351267274)
67. Watt KD, Pedersen RA, Kremers WK, Heimbach JK, Sanchez W, Gores GJ. Long-term probability of and mortality from de novo malignancy after liver transplantation. Gastroenterology 2009;137:2010-7.
68. Meyer CG, Penn I, James L. Liver transplantation for cholangiocarcinoma: Results in 207 patients. Transplantation 2000;69:1633-7.
69. Robles R, Figueras J, Turrion VS, et al. Liver transplantation for hilar cholangiocarcinoma: Spanish experience. Transplant Proc 2003;35:1821-2. (Pubitemid 37093724)
70. Rosen CB, Heimbach JK, Gores GJ. Liver transplantation for cholangiocarcinoma. Transplant Int 2010;23:692-7.
71. Farkkila M, Karvonen AL, Nurmi H, et al. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: A randomized placebo-controlled trial. Hepatology 2004;40:1379-86. (Pubitemid 39657012)
72. Silveira MG, Torok NJ, Gossard AA, et al. Minocycline in the treatment of patients with primary sclerosing cholangitis: Results of a pilot study. Am J Gastroenterol 2009;104:83-8.
73. Angulo P, Batts KP, Jorgensen RA, LaRusso NA, Lindor KD. Oral budesonide in the treatment of primary sclerosing cholangitis. Am J Gastroenterol 2000;95:2333-7.
74. Kochhar R, Goenka MK, Das K, et al. Primary sclerosing cholangitis: An experience from India. J Gastroenterol Hepatol 1996;11:429-33. (Pubitemid 26151918)
75. Lindor KD, Wiesner RH, Colwell LJ, Steiner B, Beaver S, LaRusso NF. The combination of prednisone and colchicine in patients with primary sclerosing cholangitis. Am J Gastroenterol 1991;86:57-61.
76. Kaplan MM, Arora S, Pincus SH. Primary sclerosing cholangitis and low-dose oral pulse methotrexate therapy. Clinical and histologic response. Ann Intern Med 1987;106:231-5. (Pubitemid 17009883)
77. Knox TA, Kaplan MM. Treatment of primary sclerosing cholangitis with oral methotrexate. Am J Gastroenterol 1991;86:546-52.
78. Knox TA, Kaplan MM. A double-blind controlled trial of oral-pulse methotrexate therapy in the treatment of primary sclerosing cholangitis. Gastroenterology 1994;106:494-9. (Pubitemid 24041229)
79. Gross JB, Jr., Ludwig J, Wiesner RH, McCall JT, LaRusso NF. Abnormalities in tests of copper metabolism in primary sclerosing cholangitis. Gastroenterology 1985;89:272-8. (Pubitemid 15028582)
80. Kaplan MM. Medical approaches to primary sclerosing cholangitis. Semin Liver Dis 1991;11:56-63.
81. Talwalkar JA, Angulo P, Keach JC, Petz JL, Jorgensen RA, Lindor KD. Mycophenolate mofetil for the treatment of primary sclerosing cholangitis. Am J Gastroenterol 2005;100:308-12. (Pubitemid 40314514)
82. Olsson R, Broome U, Danielsson A, et al. Colchicine treatment of primary sclerosing cholangitis. Gastroenterology 1995;108:1199-203.
83. Epstein MP, Kaplan MM. A pilot study of etanercept in the treatment of primary sclerosing cholangitis. Dig Dis Sci 2004;49:1-4. (Pubitemid 38183736)
84. Hommes DW Erkelens W, Ponsioen C, et al. A double-blind, placebo-controlled, randomized study of infliximab in primary sclerosing cholangitis. J Clin Gastroenterol 2008;42:522-6.
85. Wiesner RH, Steiner B, LaRusso NA. A controlled clinical trial evaluating cyclosporine in the treatment of primary sclerosing cholangitis. Hepatology 1991;14:63A (Abst).
86. Van Thiel DH, Carroll P, Abu-Elmagd K, et al. Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: Results of an open-label preliminary trial. Am J Gastroenterol 1995;90:455-9.